Abstract CT177: Epacadostat plus durvalumab in patients with advanced solid tumors: preliminary results of the ongoing, open-label, phase I/II ECHO-203 study
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-ct177
Abstract: Introduction: Epacadostat, a potent and highly selective oral inhibitor of the indoleamine 2,3- dioxygenase 1 (IDO1) enzyme, plus durvalumab, an anti-PD-L1 antibody, is being studied in patients with advanced solid tumors (NCT02318277). Phase 1 preliminary… read more here.
Keywords: phase; solid tumors; advanced solid; epacadostat plus ... See more keywords
Initial experience of preoperative gemcitabine and cisplatin plus durvalumab followed by resection for high-risk biliary tract cancer.
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2025.43.16_suppl.e16329
Abstract: e16329 Background: Althoughgemcitabine and cisplatin plus durvalumab (GC+D) are standard of care for metastatic biliary tract cancer (BTC), the regimen’s effectiveness in the neoadjuvant setting for resectable disease remains unkown. We sought to evaluate early… read more here.
Keywords: plus durvalumab; resection; high risk; biliary tract ... See more keywords